A-HeFT
Trial question
What is the role of isosorbide dinitrate plus hydralazine in black patients with HF?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
40.0% female
60.0% male
N = 1050
1050 patients (420 female, 630 male).
Inclusion criteria: black patients who had NYHA class III or IV HF with dilated ventricles.
Key exclusion criteria: recent acute MI, acute coronary syndrome, or stroke; recent cardiac surgery or PCI; clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy; or symptomatic hypotension.
Interventions
N=518 oral vasodilator therapy (120 mg of isosorbide dinitrate plus 225 mg of hydralazine and standard therapy for HF).
N=532 placebo (matching placebo plus standard therapy for HF).
Primary outcome
A weighted score incorporating death from any cause (-3 points), first hospitalization for heart failure (-1 points), and change in quality of life
-0.1 points
-0.5 points
0.0 points
-0.1 points
-0.3 points
-0.4 points
-0.5 points
Oral vasodilator
therapy
Placebo
Significant
increase ▲
Significant increase in a weighted score incorporating death from any cause (-3 points), first hospitalization for HF (-1 points), and change in the QoL (-0.1 points vs. -0.5 points; AD 0.4 points, 95% CI 0.1 to 0.7).
Secondary outcomes
Significant decrease in death from any cause (6.2% vs. 10.2%; HR 0.57, 95% CI 0.09 to 1.05).
Significant decrease in first hospitalization for HF (16.4% vs. 24.4%; RR 0.67, 95% CI 0.27 to 1.07).
Significantly smaller improvement in QoL score at 6 months (-5.6 points vs. -2.7 points; AD -2.9 points, 95% CI -5.35 to -0.45).
Safety outcomes
Significant differences in headache (47.5% vs. 19.2%), dizziness (29.3% vs. 12.3%), severe exacerbation of congestive HF (3.1% vs. 7.0%).
Conclusion
In black patients who had NYHA class III or IV HF with dilated ventricles, oral vasodilator therapy was superior to placebo with respect to a weighted score incorporating death from any cause (-3 points), first hospitalization for HF (-1 points), and change in the QoL.
Reference
Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004 Nov 11;351(20):2049-57.
Open reference URL